Medical illness unrelated to HL, which in the opinion of the study physician will preclude administration of chemotherapy safely; this includes patients with uncontrolled infection (including opportunistic), chronic renal failure, myocardial infarction (MI) within the past  months, unstable angina, or cardiac arrhythmias other than chronic atrial fibrillation, or second malignancy requiring active treatment
Patient must have no history of recent myocardial infarction (within three months), uncontrolled congestive heart failure, or uncontrolled cardiac arrhythmia
No serious medical conditions such as myocardial infarction within  months prior to entry, congestive heart failure, unstable ventricular arrhythmia, uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled psychotic disorders, serious infections, active peptic ulcer disease, psychiatric illness, or any other medical conditions that might be aggravated by treatment or limit compliance
Uncontrolled hypertension, unstable angina, congestive heart failure of any NYHA classification stage greater than (>) , serious cardiac arrhythmia requiring treatment (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia), history of myocardial infarction within  months of enrollment
Subjects with evidence of severe or uncontrolled systemic disease, or any concurrent condition, which could compromise participation in the study, including, but not limited to, active or uncontrolled infection, immune deficiencies (human immunodeficiency virus [HIV]-positive subjects on combination antiretroviral therapy are eligible), hepatitis B, hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past  months, uncontrolled cardiac arrhythmia, stroke/cerebrovascular accident within the past  months, or psychiatric illness/social situations which would jeopardize compliance with the protocol
Presence of uncontrolled hypertension or congestive heart failure, or acute myocardial infarction within  months of entry
COHORT : HORMONE RECEPTOR POSITIVE BREAST CANCER: Known history of cardiac arrhythmias including uncontrolled atrial fibrillation, tachyarrhythmias or bradycardia, history of congestive heart failure, or myocardial infarction or stroke in the previous  months will be excluded
COHORT : TRIPLE NEGATIVE BREAST CANCER: Known history of cardiac arrhythmias including uncontrolled atrial fibrillation, tachyarrhythmias or bradycardia, history of congestive heart failure, or myocardial infarction or stroke in the previous  months will be excluded
COHORT : ENDOMETRIAL CANCER: Known history of cardiac arrhythmias including uncontrolled atrial fibrillation, tachyarrhythmias or bradycardia, history of congestive heart failure, or myocardial infarction or stroke in the previous  months will be excluded
Patients with a history of myocardial infarction within the last  months or unstable / uncontrolled angina pectoris or history of severe and/or uncontrolled ventricular arrhythmias
Active, serious infection, medical, or psychiatric condition that would represent an inappropriate risk to the patient or would likely compromise achievement of the primary study objective, including unstable angina, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction =<  months prior to study entry
Absence of unstable cardiac disease defined as myocardial infarction with  months, uncontrolled heart failure, or uncontrolled cardiac arrhythmia
Has significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension, uncontrolled arrhythmias, or severe valvular heart disease, or a myocardial infarction within  months prior to the first dose of study treatment
Patients must have no fever or evidence of infection or other coexisting medical condition that would preclude administration of study drugs; patients with uncontrolled congestive heart failure, unstable angina and myocardial infarction within  months will be excluded
Patients with uncontrolled cardiovascular disease (a history of hospitalization for acute myocardial infarction, arrhythmia, or congestive heart failure within  months prior to registration) will be excluded
Subjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the past  months or serious uncontrolled cardiac arrhythmia are not eligible
Subjects with evidence of severe or uncontrolled systemic disease, or any concurrent condition, which could compromise participation in the study, including, but not limited to, active or uncontrolled infection, immune deficiencies, hepatitis B, hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past  months, uncontrolled cardiac arrhythmia, stroke/cerebrovascular accident within the past  months, or psychiatric illness/social situations which would jeopardize compliance with the protocol
Severe or uncontrolled, concurrent medical disease (e.g. uncontrolled diabetes, unstable angina, myocardial infarction within  months, congestive heart failure, etc.)
Patients with severe or uncontrolled concurrent medical disease (eg. uncontrolled diabetes, unstable angina, myocardial infarction within  months, congestive heart failure, etc.)
Patients with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the past  months or serious uncontrolled cardiac arrhythmia are not eligible
Any of the following concurrent severe and/or uncontrolled medical conditions:\r\n* Hypertension, labile hypertension, or history of poor compliance with antihypertensive medication\r\n* Angina pectoris\r\n* History of congestive heart failure =<  months, unless ejection fraction > %\r\n* Myocardial infarction =<  months prior to registration\r\n* Cardiac arrhythmia\r\n* Poorly controlled diabetes\r\n* Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung\r\n* Active or recent history of hemoptysis; if hemoptysis has resolved with measures such as palliative radiation therapy (e.g.  cGy over  fractions), arteriographic embolization or endobronchial interventions (e.g. photodynamic therapy, brachytherapy), etc. for >  days, patients may be considered for participation in this study\r\n* >= Grade  hypertriglyceridemia\r\n* >= Grade  hypercholesterolemia\r\n* Any illness that in the opinion of the investigator would compromise the ability of the patient to participate safely in the clinical trial
Medical illness unrelated to MCL within the prior one month that will preclude administration of chemotherapy safely; this includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past  months, unstable angina, active congestive heart failure, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis
Patient has severe or uncontrolled concurrent medical disease (e.g. uncontrolled diabetes, unstable angina, myocardial infarction within  months, congestive heart failure, etc.)
Patient has severe or uncontrolled concurrent medical disease (e.g. uncontrolled diabetes, unstable angina, myocardial infarction within  months, congestive heart failure, etc.)
Concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study such as unstable angina, myocardial infarction within  months, unstable symptomatic arrhythmia, symptomatic congestive heart failure, uncontrolled diabetes, serious active, uncontrolled infection after inadequate biliary drainage if tumor obstructing bile duct, or psychiatric illness/social situations.
Patients who have other medical conditions that would contraindicate treatment with aggressive chemotherapy (including active infection, uncontrolled hypertension, congestive heart failure, unstable angina pectoris, or myocardial infarction within the past  months, uncontrolled arrhythmia, severe pulmonary disease or requirement of supplemental oxygen)
Any severe or uncontrolled medical condition or other condition that could affect participation in this study, including: unstable angina, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction =<  months prior to study entry
Any severe or uncontrolled medical condition or other condition that could affect participation in this study, including but not limited to: unstable angina, serious uncontrolled cardiac arrhythmia, uncontrolled infection, uncontrolled hypertension, or myocardial infarction ?  months prior to study entry
Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, uncontrolled peripheral vascular disease, myocardial infarction within preceding  months, cerebrovascular accident within preceding  months, pulmonary disease impairing functional status or requiring oxygen, impairment in gastrointestinal function that may affect or alter absorption of oral medications (such as malabsorption or history of gastrectomy or bowel resection)
Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, uncontrolled peripheral vascular disease, myocardial infarction within preceding  months, cerebrovascular accident within preceding  months, pulmonary disease impairing functional status or requiring oxygen, impairment in gastrointestinal function that may affect or alter absorption of oral medications (such as malabsorption or history of gastrectomy or bowel resection)
Patients with recent (?  months) cardiac angina, difficult to control congestive\n             heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias\n             will be excluded
CLINICAL/LABORATORY CRITERIA: Patients must not have history of significant co-morbid illness inclusive of but not restricted to uncontrolled congestive cardiac failure, uncontrolled hypertension, history of myocardial infarction, unstable angina, coronary angioplasty, stenting or cerebrovascular accident within  months prior to registration or any other illness that in the assessment of the treating physician would compromise the ability of the patient to participate in this study
Myocardial infarction, symptomatic congestive heart failure, unstable angina, or serious uncontrolled cardiac arrhythmia within the last  months
Serious medical illness, including any of the following: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction, cerebrovascular event within  months prior to the screening visit
Uncontrolled cardiac disease, such as uncontrolled hypertension, unstable angina, and/or congestive heart failure requiring hospitalization within the last  months
History or presence of angina, myocardial infarction, clinically relevant valvular heart disease, uncontrolled hypertension, or congestive heart failure within the previous  months.
Major or uncontrolled comorbid conditions as determined by the treating physician:\r\n* History of ventricular arrhythmias requiring drug or device therapy\r\n* Uncontrolled angina or symptomatic congestive heart failure\r\n* Severe or uncontrolled infection requiring systemic antibiotic or antifungal therapy or active hepatitis C infection\r\n* Severe or uncontrolled psychiatric illness
Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension, unstable angina, myocardial infarction within the last  months, uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection fraction.
Has one of the following cardiac-related conditions: Congestive heart failure; angina pectoris; myocardial infarction (within  year of study start); uncontrolled hypertension; or uncontrolled arrhythmias
Concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study such as unstable angina, myocardial infarction within  months, unstable symptomatic arrhythmia, uncontrolled diabetes, serious active or uncontrolled infection
History of prior unstable angina, myocardial infarction, congestive heart failure (CHF), uncontrolled ventricular arrhythmias within  months
Uncontrolled angina within  months
Patients with evidence of uncontrolled current myocardial impairment (e.g. unstable ischemic heart disease, uncontrolled arrhythmia, symptomatic valvular dysfunction not controlled on medical therapy, uncontrolled hypertensive heart disease, and uncontrolled congestive heart failure)
Recent (=<  months) myocardial infarction, unstable angina, difficult-to-control congestive heart failure, uncontrolled hypertension on appropriate therapy, or difficult to control cardiac arrhythmias
Subjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the past  months or serious uncontrolled cardiac arrhythmia are not eligible
Myocardial infarction having occurred less than  months before inclusion, any known uncontrolled arrhythmia, symptomatic angina pectoris, active ischemia, or cardiac failure not controlled by medications
History of acute myocardial infarction within prior  months, uncontrolled angina, uncontrolled arrhythmia, or uncontrolled congestive heart failure
Patients with clinically significant illnesses which could compromise participation in the study, including, but not limited to: active or uncontrolled infection; or unstable angina pectoris, myocardial infarction within the past  months, or uncontrolled cardiac arrhythmia
Patients with evidence of severe or uncontrolled systemic disease, or any concurrent condition, which could compromise participation in the study, including, but not limited to, active or uncontrolled infection, immune deficiencies, uncontrolled hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection unless sustained virologic response to HCV therapy, uncontrolled diabetes, serious non-healing ulcer, wound or bone fracture, history of intra-abdominal abscess, abdominal fistula or gastrointestinal perforation within  days of treatment, history of pulmonary embolism in the past  months, uncontrolled hypertension, myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within  months prior to study entry, class III or IV heart failure as defined by the NYHA functional classification system, stroke/cerebrovascular accident or transient ischemic attack within the past  months or psychiatric illness/social situations which would jeopardize compliance with the protocol
Active, serious infection, medical, or psychiatric condition that would represent an inappropriate risk to the patient or would likely compromise achievement of the primary study objective, including unstable angina, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction =<  months prior to study entry
History of significant cardiovascular, neurological, endocrine, gastrointestinal, respiratory, or inflammatory illness that could preclude study participation, pose an undue medical hazard, or interfere with the interpretation of the study results, including but not limited to congestive heart failure (NYHA Class  or ), unstable angina; cardiac arrhythmia, recent (within past  months) myocardial infarction or stroke; uncontrolled hypertension; diabetes mellitus with > episodes of ketoacidosis in the preceding  months, COPD requiring > hospitalizations in preceding  months
Presence of uncontrolled hypertension or congestive heart failure, or acute myocardial infarction within  months of entry
Patients with clinically significant illnesses which could compromise participation in the study, including, but not limited to, uncontrolled infection, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past  months, uncontrolled cardiac arrhythmia, stroke/cerebrovascular accident within the past  months, or psychiatric illness/social situations that in the investigators opinion would make it undesirable for the patient to participate in the trial, or which would jeopardize compliance with the protocol
The subject has uncontrolled significant intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled congestive heart failure, unstable angina pectoris within  months, stroke within  months, myocardial infarction within  months, or uncontrolled cardiac arrhythmias, uncontrolled hypertension
Have one of the following cardiac-related conditions: Congestive heart failure or angina pectoris (except if medically controlled); myocardial infarction (within  year of study start); uncontrolled hypertension; or uncontrolled arrhythmias
Patients with congestive heart failure with ejection fraction (EF) < % or uncontrolled cardiac disease (such as uncontrolled cardiac arrhythmia, uncontrolled coronary artery disease [CAD] with active symptoms due to CAD defined as unstable angina) are excluded from initiation of study treatment
Myocardial infarction in the previous  weeks. Active ischemia or any other uncontrolled cardiac condition such as angina pectoris, significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, or CHF.
Have other severe concurrent disease or serious organ dysfunction involving the heart, kidney, liver or other organ system that may place the patient at undue risk to undergo treatment including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past  months
Serious medical illness including but not limited to uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction or cerebrovascular event with  months of registration, history of chronic active hepatitis or history of human immunodeficiency virus (HIV) or an active bacterial infection will not be eligible
Patients with serious medical illnesses, including any of the following: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction, cerebrovascular event within six months prior to study entry
Patients with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, history of myocardial infarction within the previous six months, or serious uncontrolled cardiac arrhythmia.
Patients with history of uncontrolled cardiac disease; i.e., uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior  months), uncontrolled congestive heart failure, and cardiomyopathy with an ejection fraction under %.
Uncontrolled or symptomatic angina
Life threatening illness (e.g., congestive heart failure, uncontrolled angina or myocardial infarction in the prior six months)
Any severe acute or chronic medical condition including uncontrolled diabetes mellitus, severe renal impairment, history of cardiovascular disease (uncontrolled hypertension, arterial thrombotic events in the past  months, congestive heart failure, severe or unstable angina pectoris, recent myocardial infraction within last  months or uncontrolled cardiac arrhythmia), which could impair the ability of the patient to participate to the study or interfere with interpretation of study results, or patient unable to comply with the study procedures.
History of uncontrolled cardiac disease (e.g., uncontrolled hypertension, unstable angina, myocardial infarction within prior  months, untreated known coronary artery disease, uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection fraction
The subject has uncontrolled significant intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled congestive heart failure, unstable angina pectoris within  months, stroke within  months, myocardial infarction within  months, or uncontrolled cardiac arrhythmias, uncontrolled hypertension
Congestive heart failure or uncontrolled angina pectoris, previous history of myocardial infarction within  year from study entry, uncontrolled hypertension, or dysrhythmias.
PART I: Co-morbid condition that would affect survival: end stage congestive heart failure, unstable angina, myocardial infarction within  weeks of study, uncontrolled blood sugars >=  mg/dL, participants with known chronic active hepatitis or cirrhosis
PART II: Co-morbid condition that would affect survival: end stage congestive heart failure, unstable angina, myocardial infarction within  weeks of study, uncontrolled blood sugars >= mg/dL, participants with known chronic active hepatitis or cirrhosis
History of myocardial infarction, acute inflammatory heart disease, unstable angina, or uncontrolled arrhythmia within the past  months.
Concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study such as unstable angina, myocardial infarction within  months, unstable symptomatic arrhythmia, uncontrolled diabetes, serious active or uncontrolled infection
Current uncontrolled cardiac disease; i.e., uncontrolled hypertension (diastolic blood pressure [BP] >  or systolic > ), unstable angina, recent myocardial infarction (within prior  months), uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection fraction (=< %); transmural myocardial infarction within the last  months
Uncontrolled hypertension, arrhythmia, congestive heart failure or angina; patients who have had a myocardial infarction or cardiac surgery should be at least  months from the event and free of active symptoms
Unstable systemic disease including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within  months before enrollment
No history of myocardial infarction =<  months prior to registration; no current symptomatic congestive heart failure, uncontrolled angina, or uncontrolled cardiac arrhythmias
Have a known cardiac arrhythmia, uncontrolled congestive heart failure, or acute myocardial infarction within the previous  months
Severe heart or systemic disease: evidence of documented myocardial infarction, chronic unstable angina, symptomatic congestive heart failure, uncontrolled hypertension
Severe heart or systemic disease: evidence of documented myocardial infarction, chronic unstable angina, symptomatic congestive heart failure, uncontrolled hypertension
Significant history of uncontrolled cardiac disease defined as uncontrolled hypertension, unstable angina, myocardial infarction within the last  months, and uncontrolled congestive heart failure
History of any of the following contraindications to oxybutynin:\r\n* Uncontrolled gastroesophageal reflux disease (GERD) despite appropriate therapy; if patient has history of GERD, but symptoms are well-controlled with medical treatment, patient is eligible\r\n* Ulcerative colitis\r\n* Narrow-angle glaucoma\r\n* Urinary retention\r\n* Hypersensitivity to oxybutynin or any other components of the product\r\n* Current uncontrolled hyperthyroidism\r\n* Coronary heart disease (angina or prior myocardial infarction)\r\n* Congestive heart failure\r\n* Symptomatic cardiac arrhythmias\r\n* Current uncontrolled hypertension\r\n* Myasthenia gravis\r\n* Dementia
No pre-existing medical condition(s) that preclude adherence to an unsupervised exercise program (e.g., severe orthopedic conditions, scheduled surgery within  months, paralysis and/or dementia, unstable angina, history of myocardial infarction, congestive heart failure) as assessed through oncologist approval
Uncontrolled angina, uncontrolled heart failure, or uncontrolled cardiac arrhythmia as determined by the investigator at screening. Subjects with known myocardial infarction within  months prior to randomization.
Serious medical illness, including any of the following: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction, cerebrovascular event within  months prior to study entry
Patients with a history of hypercalcemia or vitamin D toxicity, or hospitalization for treatment of angina, myocardial infarction, or congestive heart failure or psychiatric illness currently or within  days of study entry as determined by the investigator.
Significant history of uncontrolled cardiac disease defined as uncontrolled hypertension, unstable angina, myocardial infarction within the last  months, and uncontrolled congestive heart failure
